The Insider and President and COO of Oxford Square Capital Corp. (OXSQ), Saul Rosenthal, Invested in 1,188 Shares; Per Se Technologies (PSTI)’s Sentiment Is 1.67

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Logo

Sentiment for Per Se Technologies Inc (PSTI)

Per Se Technologies Inc (PSTI) investors sentiment decreased to 1.67 in 2017 Q4. It’s down -0.83, from 2.5 in 2017Q3. The ratio is negative, as 15 investment managers started new or increased equity positions, while 9 reduced and sold stock positions in Per Se Technologies Inc. The investment managers in our database now have: 3.73 million shares, down from 3.73 million shares in 2017Q3. Also, the number of investment managers holding Per Se Technologies Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 6 Increased: 8 New Position: 7.

The stock decreased 1.21% or $0.075 during the last trading session, reaching $6.115. About 79,128 shares traded. Oxford Square Capital Corp. (NASDAQ:OXSQ) has 0.00% since April 14, 2017 and is . It has underperformed by 11.55% the S&P500.

TICC Capital Corp. is a business development company, operates as a closed-end, non-diversified management investment company. The company has market cap of $313.03 million. The firm invests in both public and private companies. It has a 7.39 P/E ratio. It invests in secured and unsecured senior debt, subordinated debt, junior subordinated debt, preferred stock, and common stock.

Since December 15, 2017, it had 22 buys, and 0 sales for $1.86 million activity. $70,822 worth of Oxford Square Capital Corp. (NASDAQ:OXSQ) shares were bought by ROSENTHAL SAUL B. COHEN JONATHAN H bought $66,262 worth of stock or 10,475 shares.

Investors sentiment increased to 1.23 in Q4 2017. Its up 0.13, from 1.1 in 2017Q3. It improved, as 8 investors sold Oxford Square Capital Corp. shares while 22 reduced holdings. 15 funds opened positions while 22 raised stakes. 7.12 million shares or 2.51% more from 6.94 million shares in 2017Q3 were reported. Shell Asset, a Netherlands-based fund reported 75,807 shares. Wealthtrust accumulated 1,751 shares. Goldman Sachs Group Inc Inc holds 92,991 shares or 0% of its portfolio. Raymond James Fin Svcs Advisors holds 0% or 13,791 shares. Asset has invested 0.04% of its portfolio in Oxford Square Capital Corp. (NASDAQ:OXSQ). Jump Trading Limited Liability Company accumulated 10,725 shares. Selz Limited Liability Company holds 603,000 shares. Wells Fargo & Mn holds 0% or 110,813 shares. 264,113 are owned by Thomas J Herzfeld Inc. Jpmorgan Chase & Company accumulated 106,597 shares or 0% of the stock. Tudor Investment Et Al holds 38,057 shares or 0.01% of its portfolio. Aperio Gp Ltd invested in 24,138 shares or 0% of the stock. Pinebridge Lp reported 421 shares. Boston Private Wealth Llc invested in 45,000 shares or 0.01% of the stock. Eagle Limited Liability Company reported 26,099 shares.

Saul Rosenthal, the President and COO of Oxford Square Capital Corp made a surprising deal for 1,188 shares with an average price-per-share of $6.1 in the corporation, that are with a total value of $7,273 USD. This is not his first insider trade, in the last month, he acquired another 64,553 shares worth $396,333 USD. The probability of this transaction remaining unseen is very low, with the President and COO today holding 1.20 million shares — that is 2.35% of the total market capitalization of Oxford Square Capital Corp.

The stock decreased 1.64% or $0.02 during the last trading session, reaching $1.2. About 128,644 shares traded. Pluristem Therapeutics Inc. (PSTI) has risen 13.45% since April 14, 2017 and is uptrending. It has outperformed by 1.90% the S&P500.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $133.04 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Institutional Positions Chart